These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15568146)

  • 41. Electrophysiological findings in adolescents with atrial fibrillation who have structurally normal hearts.
    Nanthakumar K; Lau YR; Plumb VJ; Epstein AE; Kay GN
    Circulation; 2004 Jul; 110(2):117-23. PubMed ID: 15197145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
    Pecini R; Elming H; Pedersen OD; Torp-Pedersen C
    Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical assessment of antiarrhythmic agents for paroxysmal atrial fibrillation guided by modification of electrophysiologic arrhythmogenicity.
    Cosío FG
    J Cardiovasc Electrophysiol; 2005 Jun; 16(6):677; author reply 677. PubMed ID: 15946374
    [No Abstract]   [Full Text] [Related]  

  • 44. [Vernakalant for the conversion of atrial fibrillation of recent onset].
    Seoane L; Baranchuk A; Conde D
    Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
    Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
    Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease.
    Goette A; Lendeckel U
    J Am Coll Cardiol; 2004 Jun; 43(12):2363; author reply 2363-4. PubMed ID: 15193707
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug therapy for atrial fibrillation.
    Musco S; Conway EL; Kowey PR
    Med Clin North Am; 2008 Jan; 92(1):121-41, xi. PubMed ID: 18061001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atrium-specific Kir3.x determines inducibility, dynamics, and termination of fibrillation by regulating restitution-driven alternans.
    Bingen BO; Neshati Z; Askar SF; Kazbanov IV; Ypey DL; Panfilov AV; Schalij MJ; de Vries AA; Pijnappels DA
    Circulation; 2013 Dec; 128(25):2732-44. PubMed ID: 24065610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atrial fibrillation: the rate versus rhythm management controversy.
    Camm AJ; Savelieva I
    J R Coll Physicians Edinb; 2012; 42 Suppl 18():23-34. PubMed ID: 22518391
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation.
    Chandra P; Rosen TS; Yeom ZH; Lee K; Kim HY; Danilo P; Rosen MR
    Europace; 2004 Sep; 6(5):384-91. PubMed ID: 15294262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atrial myofibroblast activation and connective tissue formation in a porcine model of atrial fibrillation and reduced left ventricular function.
    Lugenbiel P; Wenz F; Govorov K; Syren P; Katus HA; Thomas D
    Life Sci; 2017 Jul; 181():1-8. PubMed ID: 28546006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amiodarone and dronedarone: the worker bee and the drone?
    Franz MR; Singh SN
    Heart Rhythm; 2010 Sep; 7(9):1280-1. PubMed ID: 20620232
    [No Abstract]   [Full Text] [Related]  

  • 53. Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.
    Schmidt C; Wiedmann F; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Life Sci; 2014 Mar; 97(2):107-15. PubMed ID: 24345461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does sinus rhythm beget sinus rhythm? Effects of prompt cardioversion on the frequency and persistence of recurrent atrial fibrillation.
    Tse HF; Lau CP
    Card Electrophysiol Rev; 2003 Dec; 7(4):359-65. PubMed ID: 15071254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atrial fibrillation in congestive heart failure.
    Seiler J; Stevenson WG
    Cardiol Rev; 2010; 18(1):38-50. PubMed ID: 20010337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiarrhythmic therapy in atrial fibrillation.
    Ravens U
    Pharmacol Ther; 2010 Oct; 128(1):129-45. PubMed ID: 20624425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A technique for measurement of the extent of spatial organization of atrial activation during atrial fibrillation in the intact human heart.
    Botteron GW; Smith JM
    IEEE Trans Biomed Eng; 1995 Jun; 42(6):579-86. PubMed ID: 7790014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atrial fibrillation and renin-angiotensin system.
    Serra JL; Bendersky M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):215-23. PubMed ID: 19124423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New insights into the mechanisms and management of atrial fibrillation.
    Khairy P; Nattel S
    CMAJ; 2002 Oct; 167(9):1012-20. PubMed ID: 12403742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.
    Aguilar M; Nattel S
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):432-40. PubMed ID: 25923324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.